Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Rectal Cancer Therapeutics Pipeline Review 2016 - 7 Companies & 9 Molecules - Research and Markets

Research and Markets
Posted on: 20 Sep 16

Research and Markets has announced the addition of the "Rectal Cancer - Pipeline Review, H2 2016" report to their offering.

Rectal Cancer pipeline therapeutics constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 5, 3 and 1 respectively.

Rectal Cancer - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Rectal Cancer Overview
  3. Therapeutics Development
  4. Pipeline Products for Rectal Cancer - Overview
  5. Pipeline Products for Rectal Cancer - Comparative Analysis
  6. Rectal Cancer - Therapeutics under Development by Companies
  7. Rectal Cancer - Therapeutics under Investigation by Universities/Institutes
  8. Rectal Cancer Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Rectal Cancer - Products under Development by Companies
  13. Rectal Cancer - Products under Investigation by Universities/Institutes
  14. Rectal Cancer - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Advaxis, Inc.
  • Cerulean Pharma, Inc.
  • Hanwha Chemical Corporation
  • Karyopharm Therapeutics, Inc.
  • Regeneron Pharmaceuticals Inc
  • Taiwan Liposome Company, Ltd.

For more information about this report visit

Related Topics: Colon Cancer Drugs

View source version on

Business Wire

Last updated on: 20/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.